Keywords: AstraZeneca, rdelyz, RDX5791, Renal disease, GlaxoSmithKline, Anacor, GSK2251052, Urinary tract infection

AstraZeneca gains rights to Ardelyx program; GSK returns cUTI candidate GSK2251052 to Anacor

Article | 08 October 2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning announced a worldwide exclusive licensing agreement for closely-held USA-based Ardelyx’ NHE3 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

GlaxoSmithKline

AstraZeneca

Ardelyx

Anacor Pharmaceutical

Go to company listing

Related Drugs

RDX5791

GSK2251052

Go to drug listing